Relevant Disclosure with respect to Appointment of Secretarial and Internal Auditors is attached.
Awaiting price reaction for this filing.
Fortis Healthcare's board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with statutory auditor B S R & Co. LLP giving an unmodified opinion. Standalone revenue from operations rose to ₹144,589 lacs in FY25 from ₹118,141 lacs in FY24, but net profit fell sharply to ₹6,379 lacs (FY24: ₹19,945 lacs) due to an exceptional loss of ₹11,514 lacs from impairment of investments in subsidiaries. Q4 FY25 standalone results swung to a net loss of ₹4,223 lacs versus a profit of ₹6,833 lacs in Q4 FY24. The board recommended a final dividend of ₹1 per share (10% on face value of ₹10) for FY25. It also appointed M/s Neelam Gupta & Associates as Secretarial Auditor for 5 years (FY26–FY30) and M/s Jitender, Navneet & Co. as Cost Auditor for FY26.
Shareholders will receive a modest ₹1 dividend per share. The sharp drop in FY25 net profit and Q4 net loss, driven by a one-time subsidiary impairment, may weigh on sentiment in the near term despite healthy revenue growth.